These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6869235)

  • 41. Severe hypotension due to the use of bretylium for postcardiotomy ventricular arrhythmias.
    Kron IL; Nolan SP
    Ann Thorac Surg; 1983 Mar; 35(3):271-3. PubMed ID: 6600915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bretylium in severe ventricular arrhythmias associated with digitalis intoxication.
    Vincent JL; Dufaye P; Berre J; Kahn RJ
    Am J Emerg Med; 1984 Nov; 2(6):504-6. PubMed ID: 6529463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug therapy: bretylium.
    Koch-Weser J
    N Engl J Med; 1979 Mar; 300(9):473-7. PubMed ID: 366419
    [No Abstract]   [Full Text] [Related]  

  • 44. Lack of effect of bretylium tosylate on electrical ventricular defibrillation in a controlled study.
    Koo CC; Allen JD; Pantridge JF
    Cardiovasc Res; 1984 Dec; 18(12):762-7. PubMed ID: 6518459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of bretylium tosylate on the intraocular pressure of the rabbit.
    Krieglstein GK
    Albrecht Von Graefes Arch Klin Exp Ophthalmol; 1975 Nov; 197(2):153-8. PubMed ID: 1082263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bretylium tosylate in patients with acute myocardial infarction.
    Torresani J
    Am J Cardiol; 1984 Jul; 54(2):20A-25A. PubMed ID: 6464996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of the Na,K-ATPase by the antiarrhythmic drug, Bretylium.
    Gatto C; Barkulis CT; Schneider WR; Holden JP; Arnett KL; Milanick MA
    Ann N Y Acad Sci; 2003 Apr; 986():620-2. PubMed ID: 12763901
    [No Abstract]   [Full Text] [Related]  

  • 48. Preferential blockade of chronotropic responses to cardiac sympathetic nerve stimulation with bretylium.
    Priola DV; Weiss GK; Spurgeon HA
    Proc West Pharmacol Soc; 1977; 20():421-6. PubMed ID: 896849
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium.
    Woosley RL; Reele SB; Roden DM; Nies AS; Oates JA
    Clin Pharmacol Ther; 1982 Sep; 32(3):313-21. PubMed ID: 7105622
    [No Abstract]   [Full Text] [Related]  

  • 50. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart.
    Kowey PR; Friehling TD; O'Connor KM; Wetstein L; Kelliher GJ
    Am Heart J; 1985 Aug; 110(2):363-70. PubMed ID: 4025111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative assessment of antidysrhythmic drugs.
    Vaughan Williams EM
    G Ital Cardiol; 1972; 2(1):157. PubMed ID: 5011997
    [No Abstract]   [Full Text] [Related]  

  • 52. Cellular basis and clinical evaluation of antiarrhythmic therapy.
    Vander Ark CR; Reynolds EW
    Med Clin North Am; 1969 Nov; 53(6):1297-308. PubMed ID: 4902920
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative mechanisms of action of antiarrhythmic drugs.
    Singh BN; Hauswirth O
    Am Heart J; 1974 Mar; 87(3):367-82. PubMed ID: 4149610
    [No Abstract]   [Full Text] [Related]  

  • 54. Inactivation of acetylcholinesterase with a bretylium tosylate photoaffinity probe.
    Branchini BR; Lajiness EJ
    Biochim Biophys Acta; 1986 Oct; 884(1):135-41. PubMed ID: 3768408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of ventricular dysrhythmias in the prehospital and emergency department setting.
    Mayer NM
    Am J Cardiol; 1984 Jul; 54(2):34A-36A. PubMed ID: 6464998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The action of reserpine, 6-hydroxydopamine, and bretylium on digitalis-induced cardiotoxicity.
    Lathers CM; Gerard-Ciminera JL; Baskin SI; Krusz JC; Kelliher GJ; Roberts J
    Eur J Pharmacol; 1981 Dec; 76(4):371-9. PubMed ID: 6799304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey.
    Puddu PE; Jouve R; Saadjian A; Torresani J
    J Pharmacol; 1986; 17(3):223-43. PubMed ID: 3795968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of bretylium tosylate with rat cardiac muscarinic receptors. Possible pharmacological relevance to antiarrhythmic action.
    Schreiber G; Friedman M; Sokolovsky M
    Circ Res; 1984 Nov; 55(5):653-9. PubMed ID: 6488487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.
    Mason DT; DeMaria AN; Amsterdam EA; Zelis R; Massumi RA
    Drugs; 1973; 5(4):261-91. PubMed ID: 4146767
    [No Abstract]   [Full Text] [Related]  

  • 60. Drugs with a class III antiarrhythmic action.
    Bexton RS; Camm AJ
    Pharmacol Ther; 1982; 17(3):315-55. PubMed ID: 6761715
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.